ClinicalTrials.gg
CompletedNCT07351682Updated Oct 28, 2026

Antibacterial Activity of Calcium Hydroxide and Betamethasone in Apical Periodontitis

An interventional study of Calcium Hydroxide (Ca(OH)2) Intracanal Medication and Calcium Hydroxide + Iodoform (Metapex) in Apical Periodontitis, sponsored by Medipol University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Medipol University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Periapical Periodontitis with a site in Turkey — 13 open to participants now, 20 under way, none of them phase 3. Periapical Periodontitis · Turkey.

Enrollment
53rd of 75
45 · median 66
Started
2026
with 9 others
No phase
73 of 81
11 open now
Registered
57th of 81
by date
Lead sponsor
6 of 81
Medipol University

Among the 81 studies in Periapical Periodontitis with a site in Turkey, this one is the 53rd largest by enrollment of the 75 interventional ones that give a count, is one of 10 that started in 2026, is one of 73 with no phase, and was the 57th registered.

Periapical Periodontitis

281 studies on the registry are indexed under Periapical Periodontitis; 79 are open to participants now.

Browse Periapical Periodontitis studies →

Open to participants now

13 of the 81 studies in Periapical Periodontitis with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 43 Periapical Periodontitis studies recruiting now, 17 (40%) set no upper age limit and 25 (58%) stop at 75 or younger; 5 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Periapical Periodontitis with a site in Turkey, or all of them as a file.
02

Study summary

Apical periodontitis is a chronic inflammatory disease caused by bacterial infection of the root canal system. Although mechanical cleaning and shaping reduce most microorganisms, bacteria may persist in areas that are difficult to reach, making the use of intracanal medicaments between treatment sessions clinically important.

Calcium hydroxide is one of the most commonly used intracanal medicaments because of its antibacterial properties. However, some resistant microorganisms, such as Enterococcus faecalis, may survive when calcium hydroxide is used alone. Therefore, combining calcium hydroxide with other agents, such as iodoform or corticosteroids, may improve its antibacterial effectiveness.

The purpose of this study is to compare the antibacterial activity of calcium hydroxide used alone or in combination with iodoform (Metapex) or betamethasone in patients with apical periodontitis. Bacterial load in root canals will be evaluated using droplet digital PCR (ddPCR), a highly sensitive molecular method that allows absolute quantification of bacteria. The results of this study are expected to provide evidence to support optimal intracanal medicament selection in endodontic retreatment cases.

Read the detailed description

Apical periodontitis is a chronic inflammatory condition of periapical tissues that develops as a result of persistent bacterial infection within the root canal system. While chemomechanical preparation significantly reduces the microbial load, bacteria may remain in anatomical complexities such as dentinal tubules, isthmuses, and apical ramifications. For this reason, intracanal medicaments are widely used between treatment sessions to enhance disinfection and improve treatment outcomes.

Calcium hydroxide is the most frequently used intracanal medicament due to its high pH and antibacterial properties. Nevertheless, certain microorganisms, particularly Enterococcus faecalis, have been shown to survive in alkaline environments, limiting the effectiveness of calcium hydroxide when used alone. To overcome this limitation, calcium hydroxide has been combined with various agents, including iodoform and corticosteroids, with the aim of enhancing antibacterial activity and reducing periapical inflammation.

Droplet digital PCR (ddPCR) is a novel molecular technique that enables absolute quantification of bacterial DNA without the need for standard curves and is less affected by PCR inhibitors compared to conventional quantitative PCR methods. Despite its advantages, the use of ddPCR in clinical endodontic research remains limited, particularly in in vivo studies evaluating intracanal medicaments.

This prospective, single-center clinical study aims to compare the antibacterial efficacy of three intracanal medicament protocols in patients with apical periodontitis undergoing endodontic retreatment: (1) calcium hydroxide alone, (2) calcium hydroxide combined with iodoform (Metapex), and (3) calcium hydroxide combined with betamethasone. Root canal samples will be collected at different treatment stages, and total bacterial load as well as Enterococcus faecalis levels will be quantified using ddPCR.

The findings of this study are expected to provide high-quality clinical evidence regarding the antibacterial effectiveness of commonly used intracanal medicaments and their combinations. The results may contribute to evidence-based decision-making in the selection of intracanal medicaments for the management of apical periodontitis, particularly in retreatment cases.

03

Conditions studied

  • Apical Periodontitis

Keywords

  • Betamethasone
  • Calcium Hydroxide
  • Enterococcus faecalis
  • Droplet Digital PCR
  • Retreatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Adults aged 18 to 65 years.
  • Patients diagnosed with apical periodontitis requiring endodontic retreatment.
  • Presence of a single tooth with radiographic evidence of apical periodontitis.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Use of systemic antibiotics within the previous 3 months.
  • Presence of systemic diseases that may affect healing or immune response.
  • Pregnancy or lactation.
  • Known allergy or to any of the intracanal medicaments used.
  • Teeth with acute abscess, severe periodontal disease, or root fractures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Calcium Hydroxide

    This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive calcium hydroxide as an intracanal medicament as part of routine clinical care. The selection of the intracanal medicament is based on standard clinical decision-making and is not assigned by the study protocol.

    Other: Calcium Hydroxide (Ca(OH)2) Intracanal Medication

  • Experimental
    Calcium Hydroxide + Iodoform (Metapex)

    This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive a combination of calcium hydroxide and iodoform (Metapex) as an intracanal medicament as part of routine clinical care. The intracanal medicament is selected according to standard clinical practice and is not assigned by the study protocol.

    Other: Calcium Hydroxide + Iodoform (Metapex)

  • Experimental
    Calcium Hydroxide + Betamethasone

    This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive a combination of calcium hydroxide and betamethasone as an intracanal medicament as part of routine clinical care. The choice of intracanal medicament is determined by routine clinical decision-making and is not assigned by the study protocol.

    Other: Calcium Hydroxide + Betamethasone

Interventions

  • OtherCalcium Hydroxide (Ca(OH)2) Intracanal Medication

    In the Ch Groups CaOH was prepared and inserted into the canal by using lentülo spirals.

  • OtherCalcium Hydroxide + Iodoform (Metapex)

    Mixture of CaOH and Iodoform was inserted into the canal by using lentulo spirals.

  • OtherCalcium Hydroxide + Betamethasone

    Mixture of CaOH and bethamethasone was inserted into the canal by using lentulo spirals.

06

What researchers measure

Primary outcomes

  1. Change in Total Bacterial Load in Root Canal Samples

    The primary outcome is the change in total bacterial load in root canal samples collected during endodontic retreatment. Bacterial load will be quantified using droplet digital PCR (ddPCR) by measuring absolute bacterial DNA copy numbers at different treatment stages.

    Time frame: From baseline to 7 days after intracanal medicament application

Secondary outcomes

  1. Change in Enterococcus faecalis Levels

    This secondary outcome assesses the change in Enterococcus faecalis levels in root canal samples collected during endodontic retreatment. Enterococcus faecalis DNA will be quantified using droplet digital PCR (ddPCR) by measuring absolute DNA copy numbers before and after intracanal medicament application.

    Time frame: From baseline to 7 days after intracanal medicament application

07

Study locations

1 site
  • Istanbul Medipol University Faculty of Dentistry
    Istanbul, Istanbul 34810, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Aug 2026, 7 months.

Of 172 non-industry interventional studies with no phase under Periapical Periodontitis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 7 months is below that.

Counting every sponsor, half of 173 studies reached it within 12 months; a quarter within 6 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Mar 2026 → Jan 2026, primary completion Nov 2026 → Aug 2026 and completion Mar 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2026
First posted
Jan 20, 2026
StartActual
Jan 1, 2026was Mar 2026
Primary completionActual
Aug 30, 2026was Nov 2026
CompletionActual
Sep 2, 2026was Mar 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 28, 2026
Start date
Mar 1, 2026→Jan 1, 2026 (actual)
Oct 28, 2026
Primary completion
Nov 1, 2026→Aug 30, 2026 (actual)
Oct 28, 2026
Study completion
Mar 1, 2027→Sep 2, 2026 (actual)
Oct 28, 2026
Eligibility
Revised
Oct 28, 2026
Interventions
Arms or interventions changed
Oct 28, 2026
Sponsor
Duygu Degirmencioglu→Medipol University
Oct 28, 2026
Design
Study type Observational→Interventional
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Completed
    Start date Mar 1, 2026→Jan 1, 2026 (now actual)
    Primary completion Nov 1, 2026→Aug 30, 2026 (now actual)
    Study completion Mar 1, 2027→Sep 2, 2026 (now actual)
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor Duygu Degirmencioglu→Medipol University
    Design Study type Observational→Interventional
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351682
Lead sponsor
Medipol University
Collaborators
Istanbul Medipol University Scientific Research Projects Commission
Responsible party
Duygu Degirmencioglu (Assistant Professor, Medipol University) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 1, 2026
Primary completion
Aug 30, 2026
Completion
Sep 2, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion